204 related articles for article (PubMed ID: 23782077)
21. High-dose fast infusion of parenteral iron isomaltoside is efficacious in inflammatory bowel disease patients with iron-deficiency anaemia without profound changes in phosphate or fibroblast growth factor 23.
Dahlerup JF; Jacobsen BA; van der Woude J; Bark LÅ; Thomsen LL; Lindgren S
Scand J Gastroenterol; 2016 Nov; 51(11):1332-8. PubMed ID: 27326766
[TBL] [Abstract][Full Text] [Related]
22. A randomized trial of iron isomaltoside versus iron sucrose in patients with iron deficiency anemia.
Derman R; Roman E; Modiano MR; Achebe MM; Thomsen LL; Auerbach M
Am J Hematol; 2017 Mar; 92(3):286-291. PubMed ID: 28052413
[TBL] [Abstract][Full Text] [Related]
23. A prospective observational study of iron isomaltoside in haemodialysis patients with chronic kidney disease treated for iron deficiency (DINO).
Mikhail AI; Schön S; Simon S; Brown C; Hegbrant JBA; Jensen G; Moore J; Lundberg LDI
BMC Nephrol; 2019 Jan; 20(1):13. PubMed ID: 30630452
[TBL] [Abstract][Full Text] [Related]
24. Intravenous iron without erythropoietin for the treatment of iron deficiency anemia in patients with moderate to severe congestive heart failure and chronic kidney insufficiency.
Usmanov RI; Zueva EB; Silverberg DS; Shaked M
J Nephrol; 2008; 21(2):236-42. PubMed ID: 18446719
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetics of iron isomaltoside 1000 in patients with inflammatory bowel disease.
Nordfjeld K; Andreasen H; Thomsen LL
Drug Des Devel Ther; 2012; 6():43-51. PubMed ID: 22419860
[TBL] [Abstract][Full Text] [Related]
26. Evolution of iv iron compounds over the last century.
Macdougall IC
J Ren Care; 2009 Dec; 35 Suppl 2():8-13. PubMed ID: 19891680
[TBL] [Abstract][Full Text] [Related]
27. Intravenous iron sucrose versus oral iron supplementation for the treatment of iron deficiency anemia in patients with inflammatory bowel disease--a randomized, controlled, open-label, multicenter study.
Schröder O; Mickisch O; Seidler U; de Weerth A; Dignass AU; Herfarth H; Reinshagen M; Schreiber S; Junge U; Schrott M; Stein J
Am J Gastroenterol; 2005 Nov; 100(11):2503-9. PubMed ID: 16279906
[TBL] [Abstract][Full Text] [Related]
28. The efficacy and safety of current intravenous iron preparations for the management of iron-deficiency anaemia: a review.
Qunibi WY
Arzneimittelforschung; 2010; 60(6a):399-412. PubMed ID: 20648931
[TBL] [Abstract][Full Text] [Related]
29. Ferumoxytol: a new era of iron deficiency anemia treatment for patients with chronic kidney disease.
Kowalczyk M; Banach M; Rysz J
J Nephrol; 2011; 24(6):717-22. PubMed ID: 21956770
[TBL] [Abstract][Full Text] [Related]
30. Pharmacodynamics and safety of ferric carboxymaltose: a multiple-dose study in patients with iron-deficiency anaemia secondary to a gastrointestinal disorder.
Geisser P; Rumyantsev V
Arzneimittelforschung; 2010; 60(6a):373-85. PubMed ID: 20648929
[TBL] [Abstract][Full Text] [Related]
31. Safety and efficacy of intravenous iron isomaltoside for correction of anaemia in patients with inflammatory bowel disease in everyday clinical practice.
Stein J; Walper A; Klemm W; Farrag K; Aksan A; Dignass A
Scand J Gastroenterol; 2018 Sep; 53(9):1059-1065. PubMed ID: 30222479
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of toxicity and oxidative stress induced by intravenous iron isomaltoside 1000 in a nonclinical model.
Toblli JE; Cao G; Oliveri L; Angerosa M
Arzneimittelforschung; 2011; 61(10):553-65. PubMed ID: 22164963
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetics, safety and tolerability of intravenous ferric carboxymaltose: a dose-escalation study in volunteers with mild iron-deficiency anaemia.
Geisser P; Banké-Bochita J
Arzneimittelforschung; 2010; 60(6a):362-72. PubMed ID: 20648928
[TBL] [Abstract][Full Text] [Related]
34. Safety and efficacy of iron isomaltoside 1000/ferric derisomaltose versus iron sucrose in patients with chronic kidney disease: the FERWON-NEPHRO randomized, open-label, comparative trial.
Bhandari S; Kalra PA; Berkowitz M; Belo D; Thomsen LL; Wolf M
Nephrol Dial Transplant; 2021 Jan; 36(1):111-120. PubMed ID: 32049331
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of oral iron(III) polymaltose complex versus ferrous sulfate in pregnant women with iron-deficiency anemia: a multicenter, randomized, controlled study.
Ortiz R; Toblli JE; Romero JD; Monterrosa B; Frer C; Macagno E; Breymann C
J Matern Fetal Neonatal Med; 2011 Nov; 24(11):1347-52. PubMed ID: 21859366
[TBL] [Abstract][Full Text] [Related]
36. [Safety aspects of parenteral iron supplementation therapies in patients with chronic kidney disease].
Potthoff SA; Münch HG
Dtsch Med Wochenschr; 2013 Jun; 138(24):1312-7. PubMed ID: 23737117
[TBL] [Abstract][Full Text] [Related]
37. Randomized evaluation of efficacy and safety of ferric carboxymaltose in patients with iron deficiency anaemia and impaired renal function (REPAIR-IDA): rationale and study design.
Szczech LA; Bregman DB; Harrington RA; Morris D; Butcher A; Koch TA; Goodnough LT; Wolf M; Onken JE
Nephrol Dial Transplant; 2010 Jul; 25(7):2368-75. PubMed ID: 20466657
[TBL] [Abstract][Full Text] [Related]
38. Safety of intravenous iron isomaltoside for iron deficiency and iron deficiency anemia in pregnancy.
Wesström J
Arch Gynecol Obstet; 2020 May; 301(5):1127-1131. PubMed ID: 32270330
[TBL] [Abstract][Full Text] [Related]
39. Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency.
Toblli JE; Lombraña A; Duarte P; Di Gennaro F
J Am Coll Cardiol; 2007 Oct; 50(17):1657-65. PubMed ID: 17950147
[TBL] [Abstract][Full Text] [Related]
40. Iron replacement and supplementation in patients with chronic kidney disease.
Wazny LD; Raymond CB
CANNT J; 2011; 21(4):26-30; quiz 31-2. PubMed ID: 22324122
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]